PRTCL Stock Overview
Engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
PureTech Health plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.22 |
| 52 Week High | UK£2.39 |
| 52 Week Low | UK£1.39 |
| Beta | 0.98 |
| 1 Month Change | 0.91% |
| 3 Month Change | 8.58% |
| 1 Year Change | -5.74% |
| 3 Year Change | -36.80% |
| 5 Year Change | -2.85% |
| Change since IPO | 64.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| PRTCL | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -2.6% | -5.0% | -1.5% |
| 1Y | -5.7% | -28.2% | 3.8% |
Return vs Industry: PRTCL exceeded the UK Biotechs industry which returned -28.2% over the past year.
Return vs Market: PRTCL underperformed the UK Market which returned 3.8% over the past year.
Price Volatility
| PRTCL volatility | |
|---|---|
| PRTCL Average Weekly Movement | 4.4% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.8% |
Stable Share Price: PRTCL has not had significant price volatility in the past 3 months.
Volatility Over Time: PRTCL's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 90 | Bharatt Chowrira | www.puretechhealth.com |
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders.
PureTech Health plc Fundamentals Summary
| PRTCL fundamental statistics | |
|---|---|
| Market cap | UK£598.60m |
| Earnings (TTM) | -UK£51.77m |
| Revenue (TTM) | UK£2.62m |
228.1x
P/S Ratio-11.6x
P/E RatioIs PRTCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRTCL income statement (TTM) | |
|---|---|
| Revenue | US$3.33m |
| Cost of Revenue | US$96.24m |
| Gross Profit | -US$92.90m |
| Other Expenses | -US$27.21m |
| Earnings | -US$65.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | -2,789.94% |
| Net Profit Margin | -1,972.88% |
| Debt/Equity Ratio | 24.8% |
How did PRTCL perform over the long term?
See historical performance and comparison